P/E ratio for VistaGen Therapeutics (VTGN)
P/E ratio as of May 2024 (TTM): -0.7164
According to VistaGen Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.716375. At the end of 2022 the company had a P/E ratio of -0.0107.
P/E ratio history for VistaGen Therapeutics from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0107 | -94.67% |
| 2021 | -0.2008 | -19.26% |
| 2020 | -0.2487 | 527.2% |
| 2019 | -0.0397 | -26.29% |
| 2018 | -0.0538 | 99.21% |
| 2017 | -0.0270 | 6.44% |
| 2016 | -0.0254 | 139.35% |
| 2015 | -0.0106 | -70.97% |
| 2014 | -0.0365 | -44.84% |
| 2013 | -0.0662 | 243.2% |
| 2012 | -0.0193 | -87.66% |
| 2011 | -0.1563 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.30 | 499.99% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.